Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024668

Director sold 518 shares at $27.54 ($14,264)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Heyman Richard A. Director 2024-10-01 Sale 10b5-1 −518 $27.54 $14,264 128,585 D
Open-market sales · 518 sh · avg $27.54 · $14,264
Loading xslF345X05/form4-10032024_101042.xml…